Endometrial Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major endometrial cancer markets reached a value of US$ 20.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 29.5 Billion by 2034, exhibiting a growth rate (CAGR) of 3.29% during 2024-2034.
The endometrial cancer market has been comprehensively analyzed in IMARC's new report titled "Endometrial Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Endometrial or uterine cancer is a type of oncological disease in which the cells in the uterus lining start to grow abnormally. This ailment mostly develops after menopause. Depending on the histology, endometrial cancer is classified into many types, but the most prevalent kind is endometrioid carcinoma. In several cases, vaginal bleeding that is not related to a menstrual period is the initial symptom of the condition. The other less common symptoms include pelvic pain, pain during sexual activity and urination, clear or thin white vaginal discharge in postmenopausal women, etc. Endometrial cancer diagnosis typically begins with a pelvic exam and pap smear to look for any abnormalities in the cervix or uterus. If any anomalies are detected, several tests may be performed, such as an ultrasound, hysteroscopy, endometrial biopsy, etc., to evaluate the thickness and appearance of the endometrium. If endometrial cancer is suspected, various additional imaging tests, including a CT scan and MRI, may be done to determine the extent of the cancer and whether it has spread to other parts of the body. Ultimately, a definitive diagnosis of the ailment is made through a biopsy of the uterine lining or tissue samples.
The rising cases of autosomal dominant genetic disorders causing gene variation and mutations in the DNA are primarily driving the endometrial cancer market. In addition to this, the increasing incidences of several associated risk factors, including advancing age, obesity, hormonal imbalance, use of the drug tamoxifen, utilization of an intrauterine device, etc., are also bolstering the market growth. Furthermore, the widespread adoption of brachytherapy, in which a minimal source of radiation is delivered directly to the affected area to kill cancer cells, is acting as another significant growth-inducing factor. Apart from this, the escalating demand for combination therapy, such as surgery followed by radiation therapy, owing to improved patient outcomes, is also creating a positive outlook for the market. Radiation therapy is used to eliminate any leftover cancer cells after surgery in cases where cancer has spread beyond the uterus but is still confined to the pelvis. Moreover, the increasing utilization of sentinel lymph node mapping to identify the lymph nodes that are most likely to contain cancer cells, which further helps doctors determine the extent of the cancer and plan more targeted treatments, is also augmenting the market growth. Additionally, the emerging popularity of fertility-sparing surgery, including hysteroscopic resection and fertility-sparing hysterectomy, among women with early-stage cancer who wish to preserve their reproductive function, is expected to drive the endometrial cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the endometrial cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for endometrial cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the endometrial cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the endometrial cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the endometrial cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current endometrial cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the endometrial cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the endometrial cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the endometrial cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of endometrial cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of endometrial cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of endometrial cancer by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of endometrial cancer by type across the seven major markets?
How many patients are diagnosed (2018-2034) with endometrial cancer across the seven major markets?
What is the size of the endometrial cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of endometrial cancer?
What will be the growth rate of patients across the seven major markets?
Endometrial Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for endometrial cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the endometrial cancer market?
What are the key regulatory events related to the endometrial cancer market?
What is the structure of clinical trial landscape by status related to the endometrial cancer market?
What is the structure of clinical trial landscape by phase related to the endometrial cancer market?
What is the structure of clinical trial landscape by route of administration related to the endometrial cancer market?
The endometrial cancer market has been comprehensively analyzed in IMARC's new report titled "Endometrial Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Endometrial or uterine cancer is a type of oncological disease in which the cells in the uterus lining start to grow abnormally. This ailment mostly develops after menopause. Depending on the histology, endometrial cancer is classified into many types, but the most prevalent kind is endometrioid carcinoma. In several cases, vaginal bleeding that is not related to a menstrual period is the initial symptom of the condition. The other less common symptoms include pelvic pain, pain during sexual activity and urination, clear or thin white vaginal discharge in postmenopausal women, etc. Endometrial cancer diagnosis typically begins with a pelvic exam and pap smear to look for any abnormalities in the cervix or uterus. If any anomalies are detected, several tests may be performed, such as an ultrasound, hysteroscopy, endometrial biopsy, etc., to evaluate the thickness and appearance of the endometrium. If endometrial cancer is suspected, various additional imaging tests, including a CT scan and MRI, may be done to determine the extent of the cancer and whether it has spread to other parts of the body. Ultimately, a definitive diagnosis of the ailment is made through a biopsy of the uterine lining or tissue samples.
The rising cases of autosomal dominant genetic disorders causing gene variation and mutations in the DNA are primarily driving the endometrial cancer market. In addition to this, the increasing incidences of several associated risk factors, including advancing age, obesity, hormonal imbalance, use of the drug tamoxifen, utilization of an intrauterine device, etc., are also bolstering the market growth. Furthermore, the widespread adoption of brachytherapy, in which a minimal source of radiation is delivered directly to the affected area to kill cancer cells, is acting as another significant growth-inducing factor. Apart from this, the escalating demand for combination therapy, such as surgery followed by radiation therapy, owing to improved patient outcomes, is also creating a positive outlook for the market. Radiation therapy is used to eliminate any leftover cancer cells after surgery in cases where cancer has spread beyond the uterus but is still confined to the pelvis. Moreover, the increasing utilization of sentinel lymph node mapping to identify the lymph nodes that are most likely to contain cancer cells, which further helps doctors determine the extent of the cancer and plan more targeted treatments, is also augmenting the market growth. Additionally, the emerging popularity of fertility-sparing surgery, including hysteroscopic resection and fertility-sparing hysterectomy, among women with early-stage cancer who wish to preserve their reproductive function, is expected to drive the endometrial cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the endometrial cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for endometrial cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the endometrial cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the endometrial cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the endometrial cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current endometrial cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the endometrial cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the endometrial cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the endometrial cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of endometrial cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of endometrial cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of endometrial cancer by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of endometrial cancer by type across the seven major markets?
How many patients are diagnosed (2018-2034) with endometrial cancer across the seven major markets?
What is the size of the endometrial cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of endometrial cancer?
What will be the growth rate of patients across the seven major markets?
Endometrial Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for endometrial cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the endometrial cancer market?
What are the key regulatory events related to the endometrial cancer market?
What is the structure of clinical trial landscape by status related to the endometrial cancer market?
What is the structure of clinical trial landscape by phase related to the endometrial cancer market?
What is the structure of clinical trial landscape by route of administration related to the endometrial cancer market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ENDOMETRIAL CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ENDOMETRIAL CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ENDOMETRIAL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ENDOMETRIAL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ENDOMETRIAL CANCER - UNMET NEEDS
10 ENDOMETRIAL CANCER - KEY ENDPOINTS OF TREATMENT
11 ENDOMETRIAL CANCER - MARKETED PRODUCTS
11.1 List of Endometrial Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jemperli (Dostarlimab) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ENDOMETRIAL CANCER - PIPELINE DRUGS
12.1 List of Endometrial Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Giredestrant - Genentech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Retifanlimab - Incyte Corporation/Macrogenics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Selinexor - Karyopharm Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 EG-007 - Evergreen Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SYD985 - Byondis
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ENDOMETRIAL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ENDOMETRIAL CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ENDOMETRIAL CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Endometrial Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Endometrial Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Endometrial Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Endometrial Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Endometrial Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Endometrial Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Endometrial Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Endometrial Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Endometrial Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Endometrial Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Endometrial Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Endometrial Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Endometrial Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Endometrial Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Endometrial Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Endometrial Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Endometrial Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Endometrial Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Endometrial Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Endometrial Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Endometrial Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Endometrial Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Endometrial Cancer - Access and Reimbursement Overview
16 ENDOMETRIAL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ENDOMETRIAL CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ENDOMETRIAL CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ENDOMETRIAL CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ENDOMETRIAL CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ENDOMETRIAL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ENDOMETRIAL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ENDOMETRIAL CANCER - UNMET NEEDS
10 ENDOMETRIAL CANCER - KEY ENDPOINTS OF TREATMENT
11 ENDOMETRIAL CANCER - MARKETED PRODUCTS
11.1 List of Endometrial Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jemperli (Dostarlimab) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ENDOMETRIAL CANCER - PIPELINE DRUGS
12.1 List of Endometrial Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Giredestrant - Genentech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Retifanlimab - Incyte Corporation/Macrogenics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Selinexor - Karyopharm Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 EG-007 - Evergreen Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SYD985 - Byondis
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ENDOMETRIAL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ENDOMETRIAL CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ENDOMETRIAL CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Endometrial Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Endometrial Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Endometrial Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Endometrial Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Endometrial Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Endometrial Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Endometrial Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Endometrial Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Endometrial Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Endometrial Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Endometrial Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Endometrial Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Endometrial Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Endometrial Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Endometrial Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Endometrial Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Endometrial Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Endometrial Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Endometrial Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Endometrial Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Endometrial Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Endometrial Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Endometrial Cancer - Access and Reimbursement Overview
16 ENDOMETRIAL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ENDOMETRIAL CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ENDOMETRIAL CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
